Biotecnika: "Antidote Technologies Raises $11M In Funding Round Led By Merck, To Accelerate Development Of Its Trial Matching Platform"

Biotecnika covered Antidote's funding news and shared how Merck's investment will help drive our next phase. The article writes: 

"UK-based clinical trial matching platform, Antidote Technologies, has raised £11m in a funding round led by Merck Global Health Innovation Fund (GHI) and joined by existing investors Smedvig Capital and Octopus Ventures.

The firm expects to be able to accelerate the development of capabilities for its trial matching platform – including precision medicine and EHR matching. Regulatory clearances still need to come through, but that’s expected to happen later this year."

Read more at Biotecnika.